Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Declares Dividend, Plans Share Repurchase

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Beckman Coulter said after the close of the market Thursday that its board of directors has declared a quarterly dividend of $.18 per share.

The dividend is payable on March 12 to all shareholders of record on Feb. 26. It noted that the dividend marks the 85th consecutive quarterly cash dividend payout.

Beckman Coulter also said that its board has authorized the repurchase of up to 1.5 million shares of the firm's outstanding common stock.

The firm made the announcement in conjunction with the release of its fourth-quarter and full-year 2010 financial results. Beckman Coulter reported revenue growth of 22 percent to $989.6 million for the fourth quarter, beating analysts' consensus estimate.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.